Press Releases Immutep Limited

Equities

IMM

AU000000IMM6

Market Closed - Australian S.E. Other stock markets 11:40:16 07/05/2024 am IST			5-day change	1st Jan Change
0.485 ^AUD	+3.19%		+12.79%	+40.58%

02/05	Immutep Limited Reports Positive Initial Clinical Data Reported from Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma	CI
02/05	Immutep Validates Initial Efficacy of Immunotherapy Medication in Phase Two Cancer Trial	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma	02/05	AQ
Immutep Quarterly Activities Report Q3 FY24	29/04	AQ
Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761	18/04	AQ
Wilsons - Adding Autoimmune to the indication list; Mtn Overweight, A$0.90 Tgt (Analysts: Dr Melissa Benson and Dr Shane Storey)	18/04	PU
Immutep : Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP76	18/04	PU
Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer	17/04	AQ
Immutep : Corporate Presentation	26/03	PU
Ladenburg Thalmann - Next Is Dose Optimization for BC Program; Reiterate Buy, $8.30 PT (Analyst: Ahu Demir, PhD)	06/03	PU
Wilsons - Dose it higher? Now an option; Mtn Overweight, A$0.90 Tgt (Analysts: Dr Melissa Benson and Dr Shane Storey)	05/03	PU
Immutep Announces First Clinical Data from 90mg Dosing of Efti	05/03	AQ
Immutep Quarterly Activities Report Q2 FY24	30/01	AQ
First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer	04/01	AQ
Immutep : Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer	21/12	PU
Immutep Receives A$2.6 million R&D Tax Incentive from French Government	07/12	AQ
Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial	22/11	AQ
Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma	10/11	AQ
Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma	09/11	AQ
Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer	06/11	AQ
Immutep : to Participate in November Investor Events	02/11	PU
Immutep Quarterly Activities Report Q1 FY24	31/23/31	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Immutep Limited

Equities

IMM

AU000000IMM6

Press Releases

Filters